Phaseline

Targets › CD4

CD4 (T-cell surface glycoprotein CD4): drug programs, companies and trials

6 programs from 6 companies in 12 trials: 6 Phase 1, 3 Phase 2, 2 Phase 3, 1 Phase 4; Infectious disease, Oncology, Metabolic and endocrine; next expected readout Jan 2027.

Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class II molecule:peptide complex. (UniProt, P01730)

Open in Phaseline: the race on CD4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKFostemsavir
Envelope polyprotein GP160 inhibitor
INSTI, GP120, CD4Phase 3HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant VirusJan 2027
TaiMed BiologicsTMB-365
HIV post-attachment inhibitor; monoclonal antibody that binds to CD4 receptor
CD4Phase 2HIV -1 InfectionMay 2027
PolTREGex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)
Ex vivo expanded regulatory T cell therapy
CD4, CD25, IL2RAPhase 2Presymptomatic Diabetes Type 1 (Stage 1)Dec 2032
Memorial Sloan Kettering Cancer CenterAntithymocyte globulin (ATG)
Polyclonal antibody targeting T lymphocytes; immunosuppressant
CTLA4, CD2, CD3, CD4, CD8Phase 1Myeloid Diseases; Hematologic MalignanciesMay 2027
David HoIbalizumab
T-cell surface antigen CD4 inhibitor
CD4Phase 1HIV-1-infectionMay 2027
Huda SalmanCD4CAR
CAR-T cell therapy targeting CD4 with anti-CD4 scFv derived from ibalizumab, with CD28 and
CD4Phase 1T-cell LymphomaDec 2027

Conditions

HIV Infections (3) HIV-1-infection (2) T-cell Lymphoma (1) Myeloid Diseases (1) Hematologic Malignancies (1) Human Immunodeficiency Virus (HIV) (1) HIV Infections With Multi Drug Resistant Virus (1) HIV -1 Infection (1) Presymptomatic Diabetes Type 1 (Stage 1) (1)

Modalities

mixed (3), small molecule (2), protein or peptide (1)

Companies

Huda Salman (1) Memorial Sloan Kettering Cancer Center (1) GSK (1) TaiMed Biologics (1) David Ho (1) PolTREG (1)

Related targets

CTLA4 (1) CD2 (1) CD3 (1) CD8 (1) INSTI (1) GP120 (1) CD25 (1) IL2RA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.